Abstract |
Promising results have suggested human leukocyte antigen (HLA) class II as potential target for antibody-based lymphoma therapy. Thus, antibodies against HLA class II induced apoptosis in vitro, as well as complement-dependent cytotoxicity (CDC) and effector cell-mediated cytotoxicity (ADCC). Furthermore, animal models demonstrated strong antitumor effects in vivo. Importantly, early clinical studies with antibodies Lym-1 or Hu1D10, both against HLA-DR variants, suggested therapeutic potential. However, the increased risk of serious toxicity may require an improved understanding of the clinically relevant mechanisms of action of HLA class II-directed antibodies, which may then allow generation of optimized antibody constructs to achieve optimal therapeutic efficacy.
|
Authors | Michael Dechant, Joerg Bruenke, Thomas Valerius |
Journal | Seminars in oncology
(Semin Oncol)
Vol. 30
Issue 4
Pg. 465-75
(Aug 2003)
ISSN: 0093-7754 [Print] United States |
PMID | 12939715
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- HLA-DR Antigens
- Histocompatibility Antigens Class II
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibody-Dependent Cell Cytotoxicity
(immunology)
- Antineoplastic Agents
(therapeutic use)
- Apoptosis
(immunology)
- Cytotoxicity, Immunologic
(immunology)
- HLA-DR Antigens
(immunology)
- Hematologic Neoplasms
(therapy)
- Histocompatibility Antigens Class II
(immunology)
- Humans
|